Axsome Therapeutics vs Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals reported revenue of $678 million in fiscal 2025, about the same as Axsome Therapeutics' $638 million in fiscal 2025. Axsome Therapeutics' revenue grew 65.5% in its latest year, and Kiniksa Pharmaceuticals' grew 60.1%. Axsome Therapeutics had an operating margin of -26.1%, against 11.4% at Kiniksa Pharmaceuticals. Free cash flow was −$94 million at Axsome Therapeutics and $136 million at Kiniksa Pharmaceuticals.
Side by side
| Axsome Therapeutics | Kiniksa Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $638M | $678M |
| Revenue growth | 65.5% | 60.1% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 88.5% |
| Operating margin | −26.1% | 11.4% |
| Net margin | −28.7% | 8.7% |
| Free cash flow | −$94M | $136M |
| Free cash flow margin | −14.7% | 20.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.8% | 10.6% |
| Last close | $135.68 | $93.53 |
| P/E at the last close | — | 71.4× |
| Insider trades, last 12 months | sold $112.5 million | sold $44.5 million |
| Piotroski F-score | 4 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Axsome TherapeuticsKiniksa Pharmaceuticals
Operating margin
Percent of revenue
Axsome TherapeuticsKiniksa Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Axsome TherapeuticsKiniksa Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Axsome Therapeutics and Kiniksa Pharmaceuticals pages.